Filtered By:
Condition: Heart Attack
Therapy: Thrombolytic Therapy

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 48 results found since Jan 2013.

A Narrative Review on Thrombolytics in Advanced CKD: Is it an Evidence-Based Therapy?
ConclusionsThe impact of TT on the outcomes of advanced CKD patients is poorly understood to date, with scarce data available in current guidelines and conflicting results from observational studies. Until evidence-based data from RCTs will be obtained, the clinical challenge of maximizing benefits for this high-risk subgroup lays in the hands of practicing clinicians.
Source: Cardiovascular Drugs and Therapy - September 5, 2018 Category: Cardiology Source Type: research

Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Abstract Poly(ADP-ribosyl)ation is an immediate cellular repair response to DNA damage and is catalyzed primarily by poly(ADP-ribose)polymerase-1 (PARP1), which is the most abundant of the 18 different PARP isoforms and accounts for more than 90% of the catalytic activity of PARP in the cell nucleus. Upon detection of a DNA strand break, PARP1 binds to the DNA, cleaves nicotinamide adenine dinucleotide between nicotinamide and ribose and then modifies the DNA nuclear acceptor proteins by formation of a bond between the protein and the ADP-ribose residue. This generates ribosyl-ribosyl linkages that act as a signal...
Source: Cardiovascular Toxicology - July 2, 2018 Category: Cardiology Authors: Henning RJ, Bourgeois M, Harbison RD Tags: Cardiovasc Toxicol Source Type: research

Thrombolytic Therapy In The Current Era: Myocardial Infarction And Beyond.
This article summarizes the history, evidence base and current use of thrombolytics in cardiovascular disease. . PMID: 29283052 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - December 27, 2017 Category: Drugs & Pharmacology Authors: Proctor P, Leesar MA, Chatterjee A Tags: Curr Pharm Des Source Type: research

Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms.
Authors: Francis A, Baynosa R Abstract Ischaemia-induced tissue injury has wide-ranging clinical implications including myocardial infarction, stroke, compartment syndrome, ischaemic renal failure and replantation and revascularization. However, the restoration of blood flow produces a 'second hit' phenomenon, the effect of which is greater than the initial ischaemic event and characterizes ischaemia-reperfusion (IR) injury. Some examples of potential settings of IR injury include: following thrombolytic therapy for stroke, invasive cardiovascular procedures, solid organ transplantation, and major trauma resuscitat...
Source: Diving and Hyperbaric Medicine - June 24, 2017 Category: Sports Medicine Tags: Diving Hyperb Med Source Type: research

Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports
ConclusionsHemorrhagic stroke is not the only complication of thrombolysis, ischemic stroke can occur even if it is an extremely rare complication. The two cases on which we report shed light on the association between fibrinolytic therapy and ischemic stroke, the pathophysiology of which is not well understood.
Source: Journal of Medical Case Reports - June 11, 2017 Category: General Medicine Source Type: research

Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study
ConclusionIn STEMI patients undergoing PCI within 24 hr after thrombolytic therapy, bivalirudin was associated with a strong trend toward reduced bleeding complications as compared to heparin alone or heparin plus GPI.The optimal antithrombotic regiment for urgent PCI following thrombolytic therapy is currently unknown. Our study demonstrated that use of bivalirudin during PCI following thrombolytic therapy is associated with a trend toward reduced bleeding complications compared to heparin alone or heparin plus GPI. Large randomized trials of adjunctive anticoagulation during PCI in this complex post‐thrombolytic popula...
Source: Catheterization and Cardiovascular Interventions - April 18, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Jaya R. Mallidi, Peter Robinson, Paul F. Visintainer, Amir S. Lotfi, Scott Mulvey, Gregory R. Giugliano Tags: Coronary Artery Disease Source Type: research

Translational initiatives in thrombolytic therapy
AbstractOnce thrombi have formed as part of the pathology defining myocardial infarction, ischemic stroke, peripheral arterial disease, deep venous thrombosis or other embolic disorders, the only clinically meaningful thrombolytic agents available for reversing the thrombogenic process are various plasminogen activators. These agents are enzymes that reverse fibrin polymerization underlying the coagulation process by converting endogenous plasminogen to plasmin, which cleaves the fibrin network to form increasingly smaller protein fragments, a process known as fibrinolysis. For the most part, the major clinically used thro...
Source: Frontiers of Medicine - January 22, 2017 Category: Journals (General) Source Type: research

Thrombolytic therapy-associated acute myocardial infarction in patients with acute ischemic stroke: A treatment dilemma
Acute myocardial infarction (AMI) is uncommon in the acute phase of acute ischemic stroke (AIS) and occurs in approximately 1% of the population. Here, we report a paradoxical case of AMI during tissue plasminogen activator (t-PA) infusion for AIS. We review and analyze the previously reported cases. We found that only patients with AMI which occurred after thrombolytic therapy for AIS who received an adequate combination of anticoagulation plus percutaneous coronary intervention survived their events.
Source: The American Journal of Emergency Medicine - November 21, 2016 Category: Emergency Medicine Authors: Chih-Jen Yang, Po-Chuan Chen, Chin-Sheng Lin, Chia-Lin Tsai, Shih-Hung Tsai Source Type: research

Electrocardiographic differentiation between takotsubo syndrome and acute myocardial infarction
It is crucial to differentiate between acute myocardial infarction (AMI), particularly of the ST-segment elevation (STE) AMI variety, and takotsubo syndrome (TTS), in order as swiftly as possible to implement thrombolytic therapy and/or percutaneous coronary interventions for the former. Also the potential benefits accrued by such an early diagnostic differentiation has a bearing on the urgency and timing of coronary arteriography, and the use of antiplatelet/anticoagulation regimen, particularly in patients “with multiple comorbidities such as those presenting after physical stressors such as subarachnoid hemorrhage or ...
Source: International Journal of Cardiology - August 7, 2016 Category: Cardiology Authors: John E. Madias Source Type: research

Thrombus-Targeted Theranostic Microbubbles: A New Technology towards Concurrent Rapid Ultrasound Diagnosis and Bleeding-free Fibrinolytic Treatment of Thrombosis
Conclusions: We describe a novel theranostic technology enabling simultaneous diagnosis and treatment of thrombosis, as well as monitoring of success or failure of thrombolysis. This technology holds promise for major progress in rapid diagnosis and bleeding-free thrombolysis thereby potentially preventing the often devastating consequences of thrombotic disease in many patients.
Source: Theranostics - June 5, 2016 Category: Molecular Biology Authors: Xiaowei Wang, Yannik Gkanatsas, Jathushan Palasubramaniam, Jan David Hohmann, Yung Chih Chen, Bock Lim, Christoph E Hagemeyer, Karlheinz Peter Tags: Research Paper Source Type: research

Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2)
Conclusions Our study showed that the composition of Iranian patients with ACS regarding the type of ACS is similar to that in developed European countries and is unlike that in developing countries of the Middle East and Africa. We found that our patients with ACS are treated with high levels of adherence to guideline-recommended in-hospital medications.
Source: BMJ Open - December 15, 2015 Category: Journals (General) Authors: Kassaian, S. E., Masoudkabir, F., Sezavar, H., Mohammadi, M., Pourmoghaddas, A., Kojouri, J., Ghaffari, S., Sanaati, H., Alaeddini, F., Pourmirza, B., Mir, E., on-behalf of the IPACE2 registry investigators Tags: Open access, Cardiovascular medicine, Evidence based practice, Medical management Research Source Type: research

Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up
Conclusions: Background diabetes mellitus, prior thrombolytic therapy, PAI-1 and vWF prestenting activity may be useful for MACE prediction over 28 months of follow-up.Cardiology 2015;132:176-181
Source: Cardiology - August 11, 2015 Category: Cardiology Source Type: research

Urticarial allergic reaction to alteplase: A case report (P6.243)
CONCLUSIONS: Physicians treating acute ischemic stroke with alteplase should be aware of this uncommon but potentially dangerous complication in the spectrum of anaphylactic reactions.Disclosure: Dr. Papolin has nothing to disclose. Dr. Mendes has nothing to disclose. Dr. Lange has nothing to disclose. Dr. Germiniani has nothing to disclose. Dr. Harger has nothing to disclose. Dr. Zetola has nothing to disclose. Dr. Chamma has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Papolin, L., Mendes, D., Lange, M., Germiniani, F., Harger, R., Zetola, V., Chamma, J. Tags: Cerebrovascular Disease and Interventional Neurology: Thrombolysis Complications Source Type: research

National data on stroke outcomes in Thailand
In conclusion, the prevalence and outcomes of stroke in Thailand were comparable with other countries. The era of thrombolytic therapy has just begun in Thailand.
Source: Journal of Clinical Neuroscience - January 14, 2015 Category: Neuroscience Source Type: research

Novel Thrombectomy System for Below-the-Knee and Visceral Arterial Interventions: PRISM Retrospective Interim Results
Conclusions Early experience with the Penumbra/Indigo Systems shows promising results with safe and effective mechanical thrombo-embolectomy in the peripheral arterial vasculature. Its successful use across a broad range of clinical applications including acute ischemia, removal of emboli that occurred during other endovascular procedures, and after failed thrombolysis is encouraging. Optimal technique will be discussed.
Source: Journal of Vascular and Interventional Radiology - December 23, 2014 Category: Radiology Source Type: research